chuminhua2019-11-11 16:29
11月8日,Anaptysbio公司$AnaptysBio(ANAB)$ 宣布,其临床阶段生物技术公司开发的IL-33单抗产品etokimab,在一项300名病人的2b期随机中重度特应性皮炎双盲安慰剂对照的ATLAS临床研究中,etokimab各个给药组均未能达到试验的主要终点,这表明在第16周,相对于安慰剂组,湿疹面积和严重程度指数(EAS...查看全文
网络异常请稍后再试2019-11-09 07:27
When it comes to atopic dermatitis, Dupixent is king. AnaptysBio has now officially tried and failed to usurp the throne, conceding its lead drug failed a trial in patients with the chronic inflammatory skin condition.
WE ARE THE KING!!!
$再生元制药(REGN)$ $AnaptysBio...查看全文
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-020034 Size: 6 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-020036 Size: 6 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-020039 Size: 6 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-020031 Size: 6 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019829 Size: 9 KB 网页链接
$AnaptysBio(ANAB)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-005507 Act: 33 Size: 4 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019676 Size: 11 KB 网页链接
$AnaptysBio(ANAB)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-005377 Act: 33 Size: 5 KB 网页链接
$AnaptysBio(ANAB)$ SC 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0000315066-24-001841 Act: 34 Size: 8 KB 网页链接
$AnaptysBio(ANAB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-018032 Size: 4 KB 网页链接